Search Clinical Trials
Sponsor Condition of Interest |
---|
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
Vanderbilt University Medical Center
Anemia, Sickle Cell
Sickle Cell Disease
Stroke
Sickle Cell Thalassemia
Sickle Cell-Beta0-Thalassemia
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals,
often poor and underserved, in the US. Silent and overt strokes contribute significantly to
morbidity in adults with SCD, resulting in functional impairment, challenges with school and... expand
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US. Silent and overt strokes contribute significantly to morbidity in adults with SCD, resulting in functional impairment, challenges with school and job performance, and premature death. Five NIH-funded randomized controlled trials have identified therapies to prevent silent and overt strokes in children with SCD, including monthly blood transfusion therapy (for preventing initial and recurrent strokes) and hydroxyurea (for preventing initial strokes). Despite the observation that at least 99% of children with SCD in high-income countries reach adulthood, and approximately 60% of adults will experience one or more strokes (~50% with silent strokes and ~10% with overt strokes), no stroke trials have established therapeutic approaches for adults with SCD. For adults with SCD, inadequate evidence-based guidelines exist for secondary stroke prevention strategies. Applying stroke prevention strategies in children may not be effective for stroke prevention in adults with SCD, particularly given the high rate of co-morbidities. Identifying subgroups of adults with SCD and higher incidence coupled with the contribution of established stroke risk factors in the general population (smoking, diabetes, obesity, renal disease) will provide the requisite data required for the first-ever phase III clinical trials focused on secondary stroke prevention in adults. Type: Observational Start Date: Jun 2017 |
Rare CFTR Mutation Cell Collection Protocol (RARE)
George Solomon
Cystic Fibrosis
Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator
(CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that
directly target defective CFTR are being evaluated in important clinical trials, but most
target... expand
Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that directly target defective CFTR are being evaluated in important clinical trials, but most target the most common CFTR mutation F508del. Many patients with rare CF mutations are not able to participate in those studies. The RARE study is specifically designed for people with CF caused by rare mutations. Eligible rare mutations are listed below: • CF patients who are heterozygous for pre-mature stop codons as noted below: i. one allele must be a F508del ii. the other allele must be a pre-mature stop codon mutation • CF Patients with other genotypes that require Study PI permission: i. CF patients with two mutations that are not eligible for Trikafta ii. CF patients homozygous or heterozygous (other allele must be F508del) for rare mutations of special interest (e.g., 711+3A->G, 2789+5G->A, 3272-26A->G, 3849+10kbC->T). Other rare mutations will be considered on a case by case basis This is a multi-site, specimen collection study. Investigators will collect blood, intestinal cells and nasal cells from each participant. Cells from these specimens will be used to test future CFTR modulators to see if they might work for people with study eligible rare mutations. Having cells to test in the lab is an important first step in identifying potential new therapies for people with these mutations. Type: Observational Start Date: Oct 2017 |
Predicton of Sepsis Recovery Performance Subtypes Pilot Study
University of Alabama at Birmingham
Sepsis
This study addresses critically ill sepsis patients' current literature reports of ongoing
post-hospital discharge weakness and hospital readmissions. This study is aimed at capture
and interpretation of a complex set of tests, administered during a subject's sepsis
functional... expand
This study addresses critically ill sepsis patients' current literature reports of ongoing post-hospital discharge weakness and hospital readmissions. This study is aimed at capture and interpretation of a complex set of tests, administered during a subject's sepsis functional recovery trajectory, particularly capturing hospital readmission's effects on survivors' physical function recovery. Type: Observational Start Date: Jul 2023 |
Cognitive Remediation Intervention to Prepare for Transition of Care
University of Alabama at Birmingham
Sickle Cell Disease
Cognitive Impairment
Adolescent Behavior
Self Efficacy
Health-Related Behavior
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the
Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to
prepare adolescents with sickle cell disease for transition of care.
expand
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care. Type: Interventional Start Date: Jul 2022 |
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab...
Novartis Pharmaceuticals
Sickle Cell Disease
This is a multi-center multi-national rollover study to allow continued access to
crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment
in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged
by the... expand
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator. Type: Interventional Start Date: Jun 2021 |
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
University of Utah
Autoimmune Encephalitis
Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with
anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line"
immunomodulatory therapies provided as standard-of-care, and either inebilizumab
(investigational agent)... expand
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. Type: Interventional Start Date: Mar 2022 |
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients
with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug... expand
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes, which are believed to play an important role in the development of IPF. Treatment with GKT137831 could result in significant benefit for a lung disease that has, until now, been almost invariably inexorable. This clinical trial represents the bedside application of a series of NOX translational and basic studies and discoveries, over several years, from the laboratory of Dr. Victor Thannickal. Type: Interventional Start Date: Sep 2020 |
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
University of Alabama at Birmingham
Alzheimer Disease
The primary objective of this study is to measure the concentration and the regional brain
distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the
UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to... expand
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this imaging study. Individuals participating in this AV-1451-PET/MRI study will also be enrolled in an ongoing [C-11]PiB-PET/MRI study (IRB-300001005, IND-138128), and their amyloid, tau and cognitive statuses will be compared in terms of race and vascular risk factors. Type: Interventional Start Date: Jul 2020 |
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics...
Columbia University
Internal Carotid Artery Stenosis
Cognitive Impairment
We aim to determine whether cognitive impairment attributable to cerebral hemodynamic
impairment in patients with high-grade asymptomatic carotid artery stenosis is reversible
with restoration of flow. To accomplish this aim CREST-H will add on to the NINDS-sponsored
CREST-2... expand
We aim to determine whether cognitive impairment attributable to cerebral hemodynamic impairment in patients with high-grade asymptomatic carotid artery stenosis is reversible with restoration of flow. To accomplish this aim CREST-H will add on to the NINDS-sponsored CREST-2 trial (parallel, outcome-blinded Phase 3 clinical trials for patients with asymptomatic high-grade carotid artery stenosis which will compare carotid endarterectomy plus intensive medical management (IMM) versus IMM alone (n=1,240), and carotid artery stenting plus IMM versus IMM alone (n=1,240) to prevent stroke and death). CREST-H addresses the intriguing question of whether cognitive impairment can be reversed when it arises from abnormal cerebral hemodynamic perfusion in a hemodynamically impaired subset of the CREST-2 -randomized patients. We will enroll 385 patients from CREST-2, all of whom receive cognitive assessments at baseline and yearly thereafter. We anticipate identifying 100 patients with hemodynamic impairment as measured by an inter-hemispheral MRI perfusion "time to peak" (TTP) delay on the side of stenosis. Among those who are found to be hemodynamically impaired and have baseline cognitive impairment, the cognitive batteries at baseline and at 1 year will determine if those with flow failure who are randomized to a revascularization arm in CREST-2 will have better cognitive outcomes than those in the medical-only arm compared with this treatment difference for those who have no flow failure. We hypothesize that hemodynamically significant "asymptomatic" carotid disease may represent one of the few examples of treatable causes of cognitive impairment. If cognitive decline can be reversed in these patients, then we will have established a new indication for carotid revascularization independent of the risk of recurrent stroke. Type: Observational Start Date: Jan 2018 |
Interventions to Decrease Financial Toxicity
University of Alabama at Birmingham
Cancer, Breast
Cancer Colorectal
Cancer, Ovarian
Cervical Cancer
Uterine Cancer
Financial distress affects 30-70% of cancer patients and describes the burden that patients
experience due to the costs of care (CoC). One reason may be because patients lack the
appropriate information on CoC that would help them better plan for and manage their CoC.
Therefore,... expand
Financial distress affects 30-70% of cancer patients and describes the burden that patients experience due to the costs of care (CoC). One reason may be because patients lack the appropriate information on CoC that would help them better plan for and manage their CoC. Therefore, the investigators plan to test a Proactive CoC intervention which includes a discussion with a trained educator on CoC information and a Cost Tracking tool to help patients deal with their CoC. Type: Interventional Start Date: Jun 2022 |
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
University of Alabama at Birmingham
Lymphoma
Hemophagocytic Lymphohistiocytoses
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients
with lymphoma to identify possible therapeutic strategies to improve overall survival of the
patients with lymphoma associated hemophagocytic lymphohistiocytosis.
expand
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis. Type: Observational Start Date: May 2023 |
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
The University of Texas Health Science Center, Houston
Infant, Extremely Premature
Obstetric Labor, Premature
Premature Birth
Intensive Care, Neonatal
Intensive Care Units, Neonatal
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal
Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and
practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation
at participating... expand
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals. Type: Observational [Patient Registry] Start Date: Jan 2019 |
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
University of Alabama at Birmingham
Primary Open Angle Glaucoma
Mobility refers to a person's purposeful movement through the environment from one place to
another and can be conceptualized as a continuum from bed bound (immobility) on one extreme
to making excursions to distant locations on the other extreme. Primary open-angle glaucoma... expand
Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting. Type: Observational Start Date: Jun 2019 |
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG)
and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and
computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed... expand
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG) and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future. Type: Interventional Start Date: Dec 2020 |
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted...
ECOG-ACRIN Cancer Research Group
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Invasive Breast Carcinoma
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating
further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer
who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after... expand
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment. Type: Interventional Start Date: Mar 2020 |
Comparing Two Methods to Follow Patients With Pancreatic Cysts
ECOG-ACRIN Cancer Research Group
Pancreatic Carcinoma
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts.
The study doctors want to compare more frequent monitoring vs less frequent monitoring in
order to learn which monitoring method leads to better outcome for patients with pancreatic... expand
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts. Type: Interventional Start Date: Jun 2020 |
Continuous Glucose Monitoring (CGM) in Kidney-Transplanted Adults
University of Alabama at Birmingham
Diabetes Mellitus
Kidney Transplant; Complications
Pre-existing diabetes prior KT and Early Post-Transplant Hyperglycemia (PTRH) defined as a
fasting blood glucose greater than or equal to 126 mg/dL or random glucose greater than or
equal to 200 mg/dL or requirement of insulin during the first 45 days after KT has been
associated... expand
Pre-existing diabetes prior KT and Early Post-Transplant Hyperglycemia (PTRH) defined as a fasting blood glucose greater than or equal to 126 mg/dL or random glucose greater than or equal to 200 mg/dL or requirement of insulin during the first 45 days after KT has been associated with increased risks of post-transplant organ rejection. PTRH has also been associated to high infection rates, and in some cases, early mortality. The use of continuous glucose monitoring (CGM) compared with blood glucose meter monitoring in non-transplant patients with diabetes resulted in lower HbA1C by 0.4 to 0.5% within the first three months of use without major changes in patients' antidiabetic regimen, possibly due to patients become more conscious about their diabetes status and diet. CGM free style libre-2 measures the interstitial fluid every minute and their glucose sensors are replaced every two weeks. To our knowledge there are no studies that assess the role of CGM in improving glycemic and transplant outcomes in solid organ transplant patients, mainly because access to CGM is often limited by inadequate health insurance coverage or high out-of-pocket costs. The investigators hypothesize that the intervention will be feasible and acceptable to patients, and our overarching hypothesis is that patients who wear a CGM will have better glycemic control, using a proxy measure of lower fructosamine/albumin ratio and better CGM-parameters, compared to those who did not wear it. Fructosamine represents the average glycemia for the 2 to 3 weeks prior. It is useful in any situation where glycemic control needs to be assessed over a period shorter than a month and in cases involving interference in the HbA1C measurement such as in adults with KT due to shorter red blood cell lifespan related to anemia of chronic disease. Fructosamine values vary in relation to the serum albumin concentration, which makes the fructosamine/albumin ratio the ideal physiologic measure for this pilot study . The investigators also hypothesize that patients who wear a CGM will have less microalbuminuria compared to those who did not wear it. Type: Interventional Start Date: Apr 2023 |
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric...
Nationwide Children's Hospital
Neuroblastoma
Sarcoma
This study will expand the types of pediatric cancers being evaluated for response to
cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma,
rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will
extend this evaluation... expand
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted. The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure. Type: Interventional Start Date: Oct 2021 |
Coaching Dementia Caregivers to Master Care-Resistant Behavior
University of Alabama at Birmingham
Care-resistant Behavior
Dementia
266 family caregivers will be randomly assigned to either immediate intervention or delayed
intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily
diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will
complete... expand
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries followed by an intermittent survey, then complete 12 weeks of CuRB-IT, and complete 2 rounds of 3--week daily diaries followed by an intermittent survey at 12-week intervals for the next 18 weeks. Type: Interventional Start Date: Apr 2023 |
Trikafta in Cystic Fibrosis Patients
Emory University
Cystic Fibrosis
This clinical study will enroll 42 participants without the F508del mutation, carrying
partial function or N1303K mutations not approved for Trikafta, and who are not expected to
be approved for CFTR modulator treatment in the immediate future. Each participant will be
given... expand
This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future. Each participant will be given Trikafta for approximately four weeks. The study researchers will monitor clinical endpoints that include forced expiratory volume (FEV1) and sweat chloride. Additionally, the researchers will obtain skin biopsy material and/or blood sample from each subject so that induced pluripotent stem (iPS) cells can be modified into airway cell monolayers and tested for response to Trikafta. In this way, the study will evaluate an emerging and readily accessible in vitro endpoint as a predictor of clinical response. This study will serve as a pilot/test case for other clinical protocols relevant to patients with rare CFTR variants who do not currently receive modulator therapies. It is hypothesized that a robust correlation will be established between in vitro Trikafta responsiveness of iPS cells and in vivo benefit (FEV1) to patients, and will provide a new tool for utilizing iPS to identify patient populations most suitable for cystic fibrosis modulator therapy. Type: Interventional Start Date: Sep 2019 |
Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery
University of Alabama at Birmingham
Dysphagia
Dysphonia
Evaluate voice and swallowing outcomes post operatively.
expand
Evaluate voice and swallowing outcomes post operatively. Type: Observational Start Date: Oct 2009 |
Effects of Early Weight Bearing on Rehabilitation Outcomes in Patients With Traumatic Ankle and Tibial...
Major Extremity Trauma Research Consortium
Rehabilitation
The overall objective of this study is to compare outcomes following early versus delayed
weight bearing for adult patients operatively treated for an ankle fracture without
syndesmotic fixation. Additionally, early weight bearing will be tested in patients with
unicondylar... expand
The overall objective of this study is to compare outcomes following early versus delayed weight bearing for adult patients operatively treated for an ankle fracture without syndesmotic fixation. Additionally, early weight bearing will be tested in patients with unicondylar plateau fractures that do not involve joint impaction in the context of a pilot study. Type: Interventional Start Date: Jan 2020 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
Breast Neoplasms
Breast Cancer
Breast Tumors
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine
by learning which new drug agents are most effective with which types of breast cancer tumors
and by learning more about which early indicators of response (tumor analysis prior to... expand
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success. Type: Interventional Start Date: Mar 2010 |
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who...
Telios Pharma, Inc.
Myelofibrosis
Primary Myelofibrosis
Post-PV MF
Post-ET Myelofibrosis
This study evaluates TL-895, a potent, orally-available and highly selective irreversible
tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF,
Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal
response... expand
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib. Type: Interventional Start Date: Jun 2022 |
HyperArc Registry Study
Varian, a Siemens Healthineers Company
Brain Metastases
CNS Neoplasm
CNS Disorder, Intracranial
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc
procedure can be assessed and compared to alternative treatments.
expand
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments. Type: Observational [Patient Registry] Start Date: Mar 2022 |
- Previous
- Next